Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received a 2nd tentative approval by the United States Food & Drug Administration (U.S. FDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza® Tablets, 2.5 mg and 5 mg, of AstraZeneca AB. Glenmark's first tentative approval letter for Saxagliptin Tablets, 2.5 mg and 5 mg was received on June 12, 2017.

According to IQVIATM sales data for the 12-month period ending December 2022, the Onglyza® Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately $122.3 million*.

Glenmark's current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 435.15 as compared to the previous close of Rs. 429.40. The total number of shares traded during the day was 23729 in over 1438 trades.

The stock hit an intraday high of Rs. 437.40 and intraday low of 425.10. The net turnover during the day was Rs. 10305073.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USASubsidiary 2nd TentativeApproval SaxagliptinTablets